The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InJaguar Health (NASDAQ: JAGX) has announced the completion of its effectiveness study for crofelemer delayed-release tablets, aimed at treating chemotherapy-induced diarrhea (CID) in dogs. The study was designed to provide the clinical data required to transition the drug from its current conditional FDA approval to full regulatory approval. The treatment is presently marketed under the brand name Canalevia-CA1 for veterinary use. Management expects to release the topline results from this trial within the next month. This milestone is a critical step in the company's strategy to monetize its animal health pipeline and expand its commercial footprint. Investors are closely watching the upcoming data as a potential catalyst for the micro-cap biotech stock.